Form 4: Veracyte Executive Phillip G. Febbo Reports Acquisition of Restricted Stock Units

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., reports the acquisition of restricted stock units and a disposition of common stock on March 6, 2024.

Summary

• On March 6, 2024, Phillip G. Febbo, the Chief Scientific & Medical Officer of Veracyte, Inc., acquired 39,904 restricted stock units.
• The restricted stock units vest 25% on March 2, 2025, and then 1/16 per quarter thereafter, contingent upon continued employment.
• On the same day, Mr. Febbo disposed of 93,086 shares of common stock.
• Following these transactions, Mr. Febbo beneficially owns 93,086 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting transactions by an insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Future Outlook

The vesting schedule of the restricted stock units is contingent upon the continued employment of the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the holdings of a key executive at Veracyte.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the holdings of a key executive.
• The vesting schedule of the restricted stock units incentivizes the executive to remain with the company.

Key Dates